Michael Schweizer News Today

Petros Grivas, MD, PhD, discusses the role of single-agent and combination PARP inhibitor regimens in prostate cancer, as well as the importance of genetic testing in this setting, the role of adjuvant regimens in resected renal cell carcinoma, and more.

The Food and Drug Administration is reportedly expediting the review of Ambrx’s treatment for patients with metastatic, castration-resistant prostate cancer that has displayed promising early trial results.

Experts have expressed concern that men with low-risk disease who are currently followed with active surveillance may be targeted with expensive therapies that have potentially serious side effects.

2022 ASCO Genitourinary (GU) Cancers Symposium, Veracyte Announces New Data at ASCO GU 2022, phase 3 study evaluating the Decipher genomic classifier.